HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, reported financial and operational results for the third quarter ended Sept. 30, 2026. The company recorded a net loss of $3 million, or $0.05 per share, compared with a net loss of $5.3 million, or $0.15 per share, in the prior-year period. Operating expenses declined to $3.5 million from $5.3 million, while cash and cash equivalents totaled $6.1 million as of Sept. 30, 2026. HeartBeam also raised approximately $4 million in net proceeds during the fourth quarter through the date of the announcement, bringing pro forma cash to approximately $10.1 million. The company now expects full-year 2026 net operating cash outflow of $12 million to $12.5 million.
Operationally, HeartBeam advanced its strategic focus on heart attack assessment, receiving U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designation and acceptance into the agency’s Total Product Life Cycle Advisory Program (“TAP”). The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms (“ECGs”) with comparable sensitivity. HeartBeam plans to finalize the design of its U.S. pivotal study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027. To view the full press release, visit https://ibn.fm/8CLXO.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. For details on the intended use of its technology, refer to the company’s Cleared Indications for Use at https://www.heartbeam.com/indications.
InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions, including InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
